Cheng-Wen Lin, PhD (林振文 博士)

Professor Department of Medical Laboratory Science and Biotechnology, China Medical University
Email: cwlin@mail.cmu.edu.tw
Phone: 886-4-22053366 ext. 7210
Fax: 886-4-22057414
Office: 14 F, Li-Fu Teaching Building
Mailing Address: Department of Medical Laboratory Science and Biotechnology, China Medical University
91, Hsueh-Shih Rd., Taichung, Taiwan 40402, R.O.C.
40402 台中市北區學士路91號 中國醫藥大學醫學檢驗生物技術學系



Institution Nation Department/Program Degree Dates
National Tsing-Hua University Taiwan, ROC Life Science PhD From 1997 / 8 to 2003 / 4
National Yang-Ming Medical College Taiwan, ROC Microbiology and Immunology Master From 1991 / 8 to 1993 / 7
National Yang-Ming Medical College Taiwan, ROC Medical Technology Bachelor From 1987 / 9 to 1991 / 6


Current Position

Institution Department/Program Position Duration
China Medical University Department of Medical Laboratory Science and Biotechnology Professor From 2007 / 2 to Now
China Medical University College of Health Care Associate Dean From 2014 / 8 to Now


Professional Experience

Institution Department/Program Position Duration
China Medical University Office of Student Affairs Dean From 2009 / 8 to 2014 / 7
China Medical University Department of Medical Laboratory Science and Biotechnology Director From 2006 / 8 to 2010 / 7
China Medical University Office of Academic Affairs Associate Dean From 2007 / 8 to 2009 / 7
China Medical University Department of Medical Laboratory Science and Biotechnology Associate Professor From 2003 / 8 to 2007 / 1
China Medical University Office of Academic Affairs/ curriculum Division Chief From 2003 / 8 to 2006 / 7
China Medical College Department of Medical Technology Lecture From 1993 / 8 to 2003 / 7
China Medical University Hospital Department of Laboratory Medicine Advisor From 2003 / 8 to 2013 / 7
China Medical College Hospital Department of Laboratory Medicine /Lab of clinical Microbiology Chief From 1996 / 4 to 1997 / 8




Current Research of Cheng-Wen Lin's Lab: Medical Virology and Biotechnology

Epidemic and endemic virus strains in Taiwan, including Japanese encephalitis virus, SARS coronavirus, Coronavirus NL63, Enterovirus 71, and Influenza virus are our research interesting. Our laboratory concentrates on the viral pathogenesis, anti-viral agents and viral diagnostics. We setup several research platforms, including phage display technology, Two-dimensional gel electrophoresis, LC/MS, confocal microscopy, and nanoparticle preparation. The following are the summary of our research in the recent years:

I. Viral Pathogenesis

The pathogenesis of severe acute respiratory syndrome coronavirus (SARS CoV) is an important issue for treatment and prevention of SARS. We demonstrated that SARS CoV 3C-like protease (3CLpro) induced apoptosis via caspase-3 and caspase-9 activities (FEMS Immunol Med Microbiol. 2006, 46, 375-380). Subsequently, we intended to identify potential 3CLpro-interacting cellular protein(s) using the phage-displayed human lung cDNA library. The vacuolar-H+ ATPase (V-ATPase) G1 subunit that contained a 3CLpro cleavage site-like motif was identified as a 3CLpro-interacting protein, as confirmed using the co-immunoprecipitation assay and the relative affinity assay (FEBS Letter,2005.11;579:6089-6094). Moreover, proteome analysis of the human promonocyte HL-CZ cells expressing 3CLpro was performed using two-dimensional gel electrophoresis and nanoscale capillary liquid chromatography/electrospray ionization quadrupole-time of flight (Q-TOF) mass spectrometry. Functional classification of identified up-regulated proteins indicated that protein metabolism and modification, particularly in the ubiquitin proteasome pathway, was the main biological process occurring in 3CLpro-expressing cells. Our results revealed that SARS CoV 3CLpro could be considered to induce mitochondrial-mediated apoptosis (PROTEOMICS, 2007; 7(9):1446-60). The study provides system-level insights into the interaction of 3CLpro with host cells, which will be helpful in elucidating the molecular basis of SARS CoV pathogenesis.

Japanese encephalitis virus (JEV), a mosquito-borne flavivirus, causes severe neurological disease with high mortality. Molecular mechanisms of JEV pathogenesis such as upstream apoptotic processes and pathways are not yet completely resolved or understood. In this study, JEV replication in human promonocyte cells induced time-dependent apoptosis and activated virus dose-dependent caspases 3, 8 and 9. Proteomic analysis demonstrated up- and down-regulated (more or less than 1.5-fold) proteins in JEV-infected promonocyte cells. Biological process categorization showed processes of antioxidation, free radical removal, and sulfur redox metabolism entailed many identified up- and down-regulated proteins. Down-regulation of thioredoxin, confirmed by using Western blotting, was involved in the apoptosis process of the oxidative stress response pathway. JEV infection caused increased intracellular ROS production and activation of ASK1-ERK/p38 MAPK signaling. ERK/p38 MAPK inhibitor PD98059 treatment definitely suppressed this apoptosis. Down-regulation of thioredoxin, increased intracellular ROS, and activation of ASK1-ERK/p38 MAPK signaling all were associated with JEV-induced apoptosis. These results are suggestive of an oxidative stress-pathway as a key element of JE pathogenesis. (Microbes Infect. 2010 Aug;12(8-9):643-51.)

Schematic diagram of pathways to JEV-induced apoptosis.
Fig. 1. Schematic diagram of pathways to JEV-induced apoptosis. Up- and down-regulated proteins were identified using 2DE followed by ESI/Q-TOF mass spectrometry and Western blotting, being associated with oxidative stress-, ROS- and ER stress-mediated apoptosis via the activation of ASK1-ERK1/2 and ASK1-p38 MAPK signaling.

II. Antiviral agents

The 3C-like protease (3CLpro) of SARS-coronavirus mediates the proteolytic processing of replicase polypeptides 1a and 1ab into functional proteins, becoming an important target for the drug development. We demonstrated the expression of the SARS-CoV 3CLpro in E. coli and Vero cells, and then characterized the in vitro trans-cleavage and the cell-based cis-cleavage by the 3CLpro (FEBS Letter, 2004, 574(1-3):131-7). We found that two phenolic compounds aloe emodin and hesperetin dose-dependently inhibited cleavage activity of the 3CLpro, in which the IC50 value was 366 M for aloe emodin and 8.3 M for hesperetin in the cell-based assay. The study will be useful for development of anti-SARS 3CLpro drugs (Antiviral Research ,2005.10;68:36-42). In addition, shikonin and arecoline that were identified as potential IFN-α inducers from nine components of Chinese herbal medicine were tested the antiviral efficacy on inhibiting the replication of JEV in human medulloblastoma cells and promonocyte cells. Shikonin effectively inhibits the replication of JEV in human neural and blood cell lines, which could be useful for the development of broad-spectrum agents against virus induced encephalitis.

IFN-stimulated gene 15 (ISG15), an ubiquitin-like protein, is rapidly induced by IFN-alpha/beta, and ISG15 conjugation is associated with the antiviral immune response. Japanese encephalitis virus (JEV), a mosquito-borne neurotropic flavivirus, causes severe central nervous system diseases. We investigated the potential anti-JEV effect of ISG15 over-expression. ISG15 over-expression in human medulloblastoma cells significantly reduced the JEV-induced cytopathic effect and inhibited JEV replication by reducing the viral titers and genomes (p<0.05, Student's t-test); it also increased activation of the interferon stimulatory response element (ISRE)-luciferase cis-acting reporter in JEV-infected cells (p<0.05, Chi-square test). Furthermore, Western blotting revealed that ISG15 over-expression increased phosphorylation of IRF-3 (Ser396), JAK2 (Tyr1007/1008) and STAT1 (Tyr701 and Ser727) in JEV-infected cells (P<0.05, Chi-square test). Confocal imaging indicated that nucleus translocation of transcription factor STAT1 occurred in ISG15-over-expressing cells but not in vector control cells post-JEV infection. ISG15 over-expression activated the expression of STAT1-dependent genes including IRF-3, IFN-beta, IL-8, PKR and OAS before and post-JEV infection (p=0.063, Student's t-test). The results enabled elucidation of the molecular mechanism of ISG15 over-expression against JEV, which will be useful for developing a novel treatment to combat JEV infection. (Antiviral Res. 2010 Mar;85(3):504-11.)

III. Viral diagnostics

Human herpesvirus 8 (HHV-8), also known as Kaposi’s sarcoma (KS)-associated herpesvirus (KSHV) is not routinely isolated in cell cultures, thus detection of HHV-8 specific antibodies is usually performed by recombinant protein-based and synthetic peptide-based serological assays. In our study, seroprevalence of HHV-8 DNA and antibodies in HIV-positive and negative patients was measured using nested PCR and recombinant proteins ORF66 and ORFK12-based screening (ELISA) and confirmation (Western blotting) immunoassays. (Biotechnol Lett. 2009 May;31(5):629-37.)

Virus isolation and antibody detection are routinely used for diagnosis of Japanese encephalitis virus (JEV) infection, but the low level of transient viremia in some JE patients makes JEV isolation from clinical and surveillance samples very difficult. We describe the use of gold nanoparticle-based RT-PCR and real-time quantitative RT-PCR assays for detection of JEV from its RNA genome. We tested the effect of gold nanoparticles on four different PCR systems, including conventional PCR, reverse-transcription PCR (RT-PCR), and SYBR green real-time PCR and RT-PCR assays for diagnosis in the acute phase of JEV infection. Gold nanoparticles increased the amplification yield of the PCR product and shortened the PCR time compared to the conventional reaction. In addition, nanogold-based real-time RT-PCR showed a linear relationship between Ct and template amount using ten-fold dilutions of JEV. The nanogold-based RT-PCR and real-time quantitative RT-PCR assays were able to detect low levels (1–10 000 copies) of the JEV RNA genomes extracted from culture medium or whole blood, providing early diagnostic tools for the detection of low-level viremia in the acute-phase infection. The assays described here were simple, sensitive, and rapid approaches for detection and quantitation of JEV in tissue cultured samples as well as clinical samples. (Nanotechnology 19 405101)


I. Paper

  1. Wang CY, Huang AC, Hour MJ, Huang SH, Kung SH, Chen CH, Chen IC, Chang YS, Lien JC, Lin CW*.Antiviral Potential of a Novel Compound CW-33 against Enterovirus A71 via Inhibition of Viral 2A Protease. Viruses. 2015 Jun 17;7(6):3155-71.
  2. Chang SJ, Huang SH, Lin YJ, Tsou YY, Lin CW*. Antiviral activity of Rheum palmatum methanol extract and chrysophanol against Japanese encephalitis virus. Arch Pharm Res. 2014 Sep;37(9):1117-23. (Corresponding author)
  3. Lin YJ, Liu X, Chang JS, Chien WK, Chen JH, Tsang H, Hung CH, Lin TH, Huang SM, Liao CC, Lin CW, Ho TJ, Tsai FJ. Coronary artery aneurysms occurrence risk analysis between Kawasaki disease and LRP1B gene in Taiwanese children. Biomedicine (Taipei). 2014;4:10.
  4. Jou YJ, Hua CH, Lin CD, Lai CH, Huang SH, Tsai MH, Kao JY, Lin CW*. S100A8 as potential salivary biomarker of oral squamous cell carcinoma using nanoLC-MS/MS. Clin Chim Acta. 2014 Sep 25;436:121-9. (Corresponding author)
  5. Lin YJ, Chen CY, Jeang KT, Liu X, Wang JH, Hung CH, Tsang H, Lin TH, Liao CC, Huang SM, Lin CW, Ho MW, Chien WK, Chen JH, Ho TJ, Tsai FJ. Ring finger protein 39 genetic variants associate with HIV-1 plasma viral loads and its replication in cell culture. Cell Biosci. 2014 Aug 5;4:40.
  6. Li SW, Yang TC, Lai CC, Huang SH, Liao JM, Wan L, Lin YJ, Lin CW*. Antiviral activity of aloe-emodin against influenza A virus via galectin-3 up-regulation. Eur J Pharmacol. 2014 Sep 5;738:125-32. (Corresponding author)
  7. Liao CR, Kuo YH, Ho YL, Wang CY, Yang CS, Lin CW*, Chang YS. Studies on cytotoxic constituents from the leaves of Elaeagnus oldhamii Maxim. in non-small cell lung cancer A549 cells. Molecules. 2014 Jul 4;19(7):9515-34. (Corresponding author)
  8. Lai CK, Rao YK, Chang KR, Lin CW, Su HL, Chang CS, Lai CH, Tzeng YM. 3,3',4', 5'-Tetramethoxychalcone inhibits human oral cancer cell proliferation and migration via p53-mediated mitochondrial-dependent apoptosis. Anticancer Res. 2014 Apr;34(4):1811-9.
  9. Lin CW, Huang YW, Hu RM, Yang TC. SmeOP-TolCSm Efflux Pump Contributes to the Multidrug Resistance of Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 2014 Apr;58(4):2405-8
  10. Huang TJ, Chou BH, Lin CW, Weng JH, Chou CH, Yang LM, Lin SJ. Synthesis and antiviral effects of isosteviol-derived analogues against the hepatitis B virus. Phytochemistry. 2014 Mar;99:107-14.
  11. Lin YJ, Lan YC, Lai CH, Lin TH, Huang SM, Liao CC, Lin CW, Hung CH, Tien N, Liu X, Chien WK, Chen JH, Tsai FJ. Association of promoter genetic variants in interleukin-10 and Kawasaki disease with coronary artery aneurysms. J Clin Lab Anal. 2014 Nov;28(6):461-4.
  12. Hseu YC, Senthil Kumar KJ, Chen CS, Cho HJ, Lin SW, Shen PC, Lin CW, Lu FJ, Yang HL. Humic acid in drinking well water induces inflammation through reactive oxygen species generation and activation of nuclear factor-κB/activator protein-1 signaling pathways: a possible role in atherosclerosis. Toxicol Appl Pharmacol. 2014 Jan 15;274(2):249-62.
  13. Lin YJ, Chang JS, Liu X, Hung CH, Lin TH, Huang SM, Jeang KT, Chen CY, Liao CC, Lin CW, Lai CH, Tien N, Lan YC, Ho MW, Chien WK, Chen JH, Huang YC, Tsang H, Wu JY, Chen CH, Chang LC, Tsai FJ. Association between GRIN3A gene polymorphism in Kawasaki disease and coronary artery aneurysms in Taiwanese children. PLoS One. 2013 Nov 22;8(11):e81384.
  14. Yang TC, Li SW, Lai CC, Lu KZ, Chiu MT, Hsieh TH, Wan L, Lin CW*. Proteomic analysis for Type I interferon antagonism of Japanese encephalitis virus NS5 protein. Proteomics. 2013 Dec;13(23-24):3442-56. doi: 10.1002/pmic.201300001. (Corresponding author)
  15. Wang CY, Huang SC, Lai ZR, Ho YL, Jou YJ, Kung SH, Zhang Y, Chang YS, Lin CW*. Eupafolin and Ethyl Acetate Fraction of Kalanchoe gracilis Stem Extract Show Potent Antiviral Activities against Enterovirus 71 and Coxsackievirus A16. Evid Based Complement Alternat Med. 2013;2013:591354. doi: 10.1155/2013/591354. (Corresponding author)
  16. Lan YC, Su MC, Chen CH, Huang SH, Chen WL, Tien N, Lin CW*. Epidemiology of pandemic influenza A/H1N1 virus during 2009-2010 in Taiwan. Virus Res. 2013 Oct;177(1):46-54.. (Corresponding author)
  17. Lin YJ, Lan YC, Hung CH, Lin TH, Huang SM, Liao CC, Lin CW, Lai CH, Tien N, Liu X, Ho MW, Chien WK, Chen JH, Wang JH, Tsai FJ. Variants in ZNRD1 gene predict HIV-1/AIDS disease progression in a Han Chinese population in Taiwan. PLoS One. 2013 Jul 9;8(7):e67572.
  18. Hour MJ, Huang SH, Chang CY, Lin YK, Wang CY, Chang YS, Lin CW*. Baicalein, Ethyl Acetate, and Chloroform Extracts of Scutellaria baicalensis Inhibit the Neuraminidase Activity of Pandemic 2009 H1N1 and Seasonal Influenza A Viruses. Evid Based Complement Alternat Med. 2013;2013:750803. (Corresponding author)
  19. Lu JR, Lu WW, Lai JZ, Tsai FL, Wu SH, Lin CW, Kung SH. Calcium flux and calpain-mediated activation of the apoptosis-inducing factor contribute to enterovirus 71-induced apoptosis. J Gen Virol. 2013 Jul;94(Pt 7):1477-85. doi: 10.1099/vir.0.047753-0.
  20. Lin YJ, Lai CC, Lai CH, Sue SC, Lin CW, Hung CH, Lin TH, Hsu WY, Huang SM, Hung YL, Tien N, Liu X, Chen CL, Tsai FJ. Inhibition of enterovirus 71 infections and viral IRES activity by Fructus gardeniae and geniposide. Eur J Med Chem. 2013 Apr;62:206-13.
  21. Li SW, Lin CW*. Human coronaviruses: Clinical features and phylogenetic analysis. Biomedicine (Taipei) 2013;3:43-50 (review, Corresponding author)
  22. Li SW, Yang TC, Wan L, Lin YJ, Tsai FJ, Lai CC, Lin CW*. Correlation between TGF beta-1 expression and proteomic profiling induced by SARS coronavirus papain like-protease. Proteomics. 2012 Aug 31. doi: 10.1002/pmic.201200225. [Epub ahead of print] (Corresponding author
  23. Chang SJ, Chang YC, Lu KZ, Tsou YY, Lin CW*.Antiviral Activity of Isatis indigotica Extract and Its Derived Indirubin against Japanese Encephalitis Virus. Evid Based Complement Alternat Med. 2012;2012:925830. (Corresponding author
  24. Wang CY, Huang SC, Zhang Y, Lai ZR, Kung SH, Chang YS, Lin CW*. Antiviral Ability of Kalanchoe gracilis Leaf Extract against Enterovirus 71 and Coxsackievirus A16.. Evid Based Complement Alternat Med. 2012;2012:503165. (Corresponding author)
  25. Chou HC, Lu YC, Cheng CS, Chen YW, Lyu PC, Lin CW*, Timms JF, Chan HL. Proteomic and redox-proteomic analysis of berberine-induced cytotoxicity in breast cancer cells. J Proteomics. 2012 Jun 18;75(11):3158-76. (Corresponding author)
  26. Lin YJ, Lan YC, Huang YC, Lin TH, Huang SM, Lai CC, Liu CS, Lin CW, Chen SY, Tsai FJ. Effects of cytokine and cytokine receptor gene variation on high anti-HB titers: following up on Taiwan's neonatal hepatitis B immunization program.Clin Chim Acta. 2012 Aug 16;413(15-16):1194-8.
  27. Lin YJ, Chang YC, Hsiao NW, Hsieh JL, Wang CY, Kung SH, Tsai FJ, Lan YC, Lin CW*. Fisetin and rutin as 3C protease inhibitors of enterovirus A71. J Virol Methods. 2012 Jun;182(1-2):93-8. (Corresponding author)
  28. Huang YW, Hu RM, Lin CW, Chung TC, Yang TC. NagZ-dependent and NagZ-independent mechanisms for β-lactamase expression in Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 2012 Apr;56(4):1936-41.
  29. Bai LY, Weng JR, Lo WJ, Yeh SP, Wu CY, Wang CY, Chiu CF, Lin CW*.Inhibition of hedgehog signaling induces monocytic differentiation of HL-60 cells. Leuk Lymphoma. 2012 Jun;53(6):1196-202. (Corresponding author)
  30. Chang CY, Chan HL, Lin HY, Way TD, Kao MC, Song MZ, Lin YJ, Lin CW*.Rhein induces apoptosis in human breast cancer cells. Evid Based Complement Alternat Med. 2012;2012:952504. (Corresponding author)
  31. Wu LC, Hsieh PH, Horng JT, Jou YJ, Lin CD, Cheng KF, Lin CW, Chen SY. Improved Candidate Biomarker Detection Based on Mass Spectrometry Data Using the Hilbert-Huang Transform. Protein Pept Lett. 2012 Jan;19(1):120-9.
  32. Lin CD, Tsai MH, Lin CW, Ho MW, Wang CY, Tsou YA, Kao MC, Tsai MH, Lai CH. Association of adenoid hyperplasia and bacterial biofilm formation in children with adenoiditis in Taiwan. Eur Arch Otorhinolaryngol. 2012 Feb;269(2):503-11
  33. Chen SY, Wan L, Huang CM, Huang YC, Sheu JJ, Lin YJ, Liu SP, Lan YC, Lai CH, Lin CW, Tsai CH, Tsai FJ. Association of the C-285T and A5954G polymorphisms in the DNA repair gene OGG1 with the susceptibility of rheumatoid arthritis. Rheumatol Int. 2012 May;32(5):1165-9.
  34. Lin CW, Lin HC, Huang YW, Chung TC, Yang TC. Inactivation of mrcA gene derepresses the basal-level expression of L1 and L2 β-lactamases in Stenotrophomonas maltophilia. J Antimicrob Chemother. 2011 Sep;66(9):2033-7.
  35. Lin CD, Kao MC, Tsai MH, Lai CH, Wei IH, Tsai MH, Tang CH, Lin CW, Hsu CJ, Lin CY. Transient ischemia/hypoxia enhances gentamicin ototoxicity via caspase-dependent cell death pathway. Lab Invest. 2011 Jul;91(7):1092-106.
  36. Jou YJ, Lin CD, Lai CH, Tang CH, Huang SH, Tsai MH, Chen SY, Kao JY, Lin CW*. Salivary zinc finger protein 510 peptide as a novel biomarker for detection of oral squamous cell carcinoma in early stages. Clin Chim Acta. 2011 Jul 15;412(15-16):1357-65(Corresponding author)
  37. Chen CH, Chang CP, Wu FY, Liu CL, Peng CT, Lin CW*. Prevalence of human herpesvirus 8 DNA in peripheral blood mononuclear cells of acute and chronic leukemia patients in Taiwan. FEMS Immunol Med Microbiol. 2011 Apr;61(3):356-8. (Corresponding author)
  38. Way TD, Chang CJ, Lin CW. Bioconjugated fluorescent polymeric nanoparticles for imaging and targeted therapy of HER2-overexpressing cancer cells. J Fluoresc. 2011 Jul;21(4):1669-76.
  39. Li SW, Lai CC, Ping JF, Tsai FJ, Wan L, Lin YJ, Kung SH, Lin CW*. Severe acute respiratory syndrome coronavirus papain-like protease suppressed alpha interferon-induced responses through downregulation of extracellular signal-regulated kinase 1-mediated signalling pathways. J Gen Virol. 2011 May;92(Pt 5):1127-40. (Corresponding author)
  40. Lan YC, Lin TH, Tsai JD, Yang YC, Peng CT, Shih MC, Lin YJ, Lin CW*. Molecular epidemiology of the 2005 enterovirus 71 outbreak in central Taiwan. Scand J Infect Dis. 2011 May;43(5):354-9. (Corresponding author)
  41. Yu FS, Yang JS, Yu CS, Lu CC, Chiang JH, Lin CW, Chung JG. Safrole induces apoptosis in human oral cancer HSC-3 cells. J Dent Res. 2011 Feb;90(2):168-74.
  42. Chen SY, Wan L, Huang CM, Huang YC, Sheu JJ, Lin YJ, Liu SP, Lan YC, Lai CH, Lin CW, Tsai CH, Tsai FJ. Genetic polymorphisms of the DNA repair gene MPG may be associated with susceptibility to rheumatoid arthritis. J Appl Genet. 2010;51(4):519-21.
  43. Jou YJ, Lin CD, Lai CH, Chen CH, Kao JY, Chen SY, Tsai MH, Huang SH, Lin CW*. Proteomic identification of salivary transferrin as a biomarker for early detection of oral cancer. Anal Chim Acta. 2010 Nov 29;681(1-2):41-8(Corresponding author)
  44. Hsiao NW, Chen JW, Yang TC, Orloff GM, Wu YY, Lai CH, Lan YC, Lin CW*. ISG15 over-expression inhibits replication of the Japanese encephalitis virus in human medulloblastoma cells. Antiviral Res. 2010 Mar;85(3):504-11. (Corresponding author)
  45. Lai CH, Chang NW, Lin CF, Lin CD, Lin YJ, Wan L, Sheu JJ, Chen SY, Huang YP, Sing YT, Tao TW, Lai CK, Tsai MH, Chan HL, Jou YJ, Lin CW*. Proteomics-based identification of haptoglobin as a novel plasma biomarker in oral squamous cell carcinoma. Clin Chim Acta. 2010 Jul 4;411(13-14):984-91. (Corresponding author)
  46. Huang YW, Lin CW, Hu RM, Lin YT, Chung TC, Yang TC. AmpN-AmpG operon is essential for expression of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia. Antimicrob Agents Chemother. 2010 Jun;54(6):2583-9.
  47. Yang TC, Lai CC, Shiu SL, Chuang PH, Tzou BC, Lin YY, Tsai FJ, Lin CW*. Japanese encephalitis virus down-regulates thioredoxin and induces ROS-mediated ASK1-ERK/p38 MAPK activation in human promonocyte cells. Microbes Infect. 2010 Aug;12(8-9):643-51. Epub 2010 Apr 27. (Corresponding author)
  48. Huang HL, Hsing HW, Lai TC, Chen YW, Lee TR, Chan HT, Lyu PC, Wu CL, Lu YC, Lin ST, Lin CW, Lai CH, Chang HT, Chou HC, Chan HL. Trypsin-induced proteome alteration during cell subculture in mammalian cells. J Biomed Sci. 2010 May 11;17:36.
  49. Lin YJ, Lan YC, Wan L, Huang CM, Lin CW, Hsueh KC, Chen DY, Lin TH, Tsai FJ. The NBS1 Genetic Polymorphisms and the Risk of the Systemic Lupus Erythematosus in Taiwanese Patients. J Clin Immunol. 2010 Jun 23. [Epub ahead of print]
  50. Huang YC, Lin YJ, Chang JS, Chen SY, Wan L, Sheu JJ, Lai CH, Lin CW, Liu SP, Chen CP, Tsai FJ. Single nucleotide polymorphism rs2229634 in the ITPR3 gene is associated with the risk of developing coronary artery aneurysm in children with Kawasaki disease. Int J Immunogenet. 2010 Jul 2. [Epub ahead of print]
  51. Wu YY, Lin CW, Cheng KS, Lin C, Wang YM, Lin IT, Chou YH, Hsu PN. Increased programmed death-ligand-1 expression in human gastric epithelial cells in Helicobacter pylori infection. Clin Exp Immunol. 2010 Jul 14. [Epub ahead of print].
  52. Bai LY, Weng JR, Tsai CH, Sargeant A, Lin CW, Chiu CF. OSU-03012 sensitizes TIB-196 myeloma cells to imatinib mesylate via AMP-activated protein kinase and STAT3 pathways. Leuk Res. 2010 Jun;34(6):816-20.
  53. Lin YJ, Chen RH, Wan L, Sheu JC, Huang CM, Lin CW, Chen SY, Lai CH, Lan YC, Hsueh KC, Tsai CH, Lin TH, Huang YM, Chao K, Chen DY, Tsai FJ. Association of TNF-alpha gene polymorphisms with systemic lupus erythematosus in Taiwanese patients. Lupus. 2009 Oct;18(11):974-9.
  54. Yang TC, Shiu SL, Chuang PH, Lin YJ, Wan L, Lan YC, Lin CW*.Japanese encephalitis virus NS2B-NS3 protease induces caspase 3 activation and mitochondria-mediated apoptosis in human medulloblastoma cells. Virus Res. 2009 Jul;143(1):77-85. (Corresponding author)
  55. Yang TC, Chang CP, Lan YC, Liu CL, Shih MC, Wu FY, Lin CW*. Recombinant ORF66 and ORFK12 antigens for the detection of human herpesvirus 8 antibodies in HIV-positive and -negative patients. Biotechnol Lett. 2009 May;31(5):629-37. (Corresponding author)
  56. Okazaki T, Nakahashi A, Uchiyama T, Okano T, Nagai T, Fujioka T, Takahashi S, Lin CW, Kuo CT. Quantitative scanning analysis of a cryoglobulin ring detected in sera of patients with hepatitis C using a cooling gel diffusion method. Clin Chem Lab Med. 2009;47(5):619-20.
  57. Chen SY, Wan L, Huang YC, Sheu JJ, Lan YC, Lai CH, Lin CW, Chang JS, Tsai Y, Liu SP, Lin YJ, Tsai FJ. Interleukin-18 gene 105A/C genetic polymorphism is associated with the susceptibility of Kawasaki disease. J Clin Lab Anal. 2009;23(2):71-6.  
  58. Lin CW, Huang YW, Hu RM, Chiang KH, Yang TC. The role of AmpR in regulation of L1 and L2 beta-lactamases in Stenotrophomonas maltophilia., Research in Microbiology 2009, 160:152-158
  59. Lin YJ, Wan L, Wu JY, Sheu JJ, Lin CW, Lan YC, Lai CH, Hung CH, Tsai Y, Tsai CH, Lin TH, Lin JG, Hsueh KC, Huang YM, Chang JS, Tsai FJ. HLA-E gene polymorphism associated with susceptibility to kawasaki disease and formation of coronary artery aneurysms. Arthritis Rheum. 2009 Feb;60(2):604-10.
  60. Huang SH, Yang TC, Tsai MH, Tsai IS, Lu HC, Chung PH, Wan L, Lin YJ, Lai CH, Lin CW *. Gold nanoparticle-based RT-PCR and real-time quantitative RT-PCR assays for detection of Japanese encephalitis virus. Nanotechnology 2008, 19: 405101. (Corresponding author)
  61. Lin CW*, Wu CF, Hsiao NW, Chang CY, Li SW, Wan L, Lin YJ, Lin WY. Aloe-emodin is an interferon-inducing agent with antiviral activity against Japanese encephalitis virus and enterovirus 71. Int J Antimicrob Agents. 2008;32:355-9. (Corresponding author)
  62. Lin SS, Huang HP, Yang JS, Wu JY, Hsai TC, Lin CC, Lin CW, Kuo CL, Gibson Wood W, Chung JG. DNA damage and endoplasmic reticulum stress mediated curcumin-induced cell cycle arrest and apoptosis in human lung carcinoma A-549 cells through the activation caspases cascade- and mitochondrial-dependent pathway. Cancer Lett. 2008,272: 77-90.
  63. Lin YJ, Wan L, Sheu JJ, Huang CM, Lin CW, Lan YC, Lai CH, Hung CH, Tsai Y, Tsai CH, Lin WY, Liu HP, Lin TH, Huang YM, Tsai FJ. G/T polymorphism in the interleukin-2 exon 1 region among Han Chinese systemic lupus erythematosus patients in Taiwan.Clin Immunol. 2008, 129:36-9.
  64. Lin CW*, Cheng CW, Yang TC, Li SW, Cheng MH, Wan L, Lin YJ, Lai CH, Lin WY, Kao MC. Interferon antagonist function of Japanese encephalitis virus NS4A and its interaction with DEAD-box RNA helicase DDX42. Virus Res. 2008, 137:49-55. (Corresponding author)
  65. Wan L, Lin CW, Lin YJ, Sheu JJ, Chen BH, Liao CC, Tsai Y, Lin WY, Lai CH, Tsai FJ. Type I IFN induced IL1-Ra expression in hepatocytes is mediated by activating STAT6 through the formation of STAT2: STAT6 heterodimer. J Cell Mol Med. 2008;12:876-88.
  66. Yen CY, Liu SY, Chen CH, Tseng HF, Chuang LY, Yang CH, Lin YC, Wen CH, Chiang WF, Ho CH, Chen HC, Wang ST, Lin CW, Chang HW. Combinational polymorphisms of four DNA repair genes XRCC1, XRCC2, XRCC3, and XRCC4 and their association with oral cancer in Taiwan.J Oral Pathol Med. 2008;37:271-7.
  67. Lin CS, Chang CS, Yang SS, Yeh HZ, Lin CW*. Retrospective evaluation of serum markers APRI and AST/ALT for assessing liver fibrosis and cirrhosis in chronic hepatitis B and C patients with hepatocellular carcinoma. Intern Med. 2008, 47:569-75. (Corresponding author)
  68. Lin YJ, Wan L, Sheu JJ, Huang CM, Lin CW, Lan YC, Lai CH, Hung CH, Tsai Y, Tsai CH, Lin TH, Chen CP, Tsai FJ.A/C polymorphism in the interleukin-18 coding region among Taiwanese systemic lupus erythematosus patients.Lupus. 2008;17:124-7.
  69. Lin CW*, Chang CP, Wu FY, Liu CL.Comparative prevalence of plasma human herpesvirus 8 DNA in sexual contact and intravenous injection routes of HIV transmission. FEMS Immunol Med Microbiol. 2008, 52:428-30. (Corresponding author)
  70. Bai LY, Chiu CF, Lin CW, Hsu NY, Lin CL, Lo WJ, Kao MC. Differential expression of Sonic hedgehog and Gli1 in hematological malignancies..Leukemia 2008, 22:226-8.
  71. Lin CW*, Liu KT, Huang HD, Chen WJ. Protective immunity of E. coli-synthesized NS1 protein of Japanese encephalitis virus. Biotechnol Lett. 2008, 30:205-14. (Corresponding author)
  72. Lin CW, Hu RM, Huang SC, Hsiao YJ, Yang TC. Induction potential of clavulanic acid toward L1 and L2 beta-lactamases of Stenotrophomonas maltophilia. Eur J Clin Microbiol Infect Dis. 2008, 27:1273-5.
  73. Lin CW, Chiou CS, Chang YC, Yang TC. Comparison of pulsed-field gel electrophoresis and three rep-PCR methods for evaluating the genetic relatedness of Stenotrophomonas maltophilia isolates. Letters in Applied Microbiology 2008, 47: 393–398
  74. Hu RM, Chiang KH, Lin CW, Yang TC. Modified nitrocefin-EDTA method to differentially quantify the induced L1 and L2 b-lactamases in Stenotrophomonas maltophilia. Letters in Applied Microbiology 2008, 47: 457–461
  75. Lai CC, Jou MJ, Huang SY, Li SW, Wan L, Tsai FJ, Lin CW*. Proteomic analysis of up-regulated proteins in human promonocyte cells expressing severe acute respiratory syndrome coronavirus 3C-like protease.. PROTEOMICS 2007, 7:1446-60. (Corresponding author)
  76. LinCW*, Huang HD, Shiu SY, Chen WJ, Tsai MH, Huang SH, Wan L, Lin YJ. Functional determinants of NS2B for activation of Japanese encephalitis virus NS3 protease. Virus Res. 2007, 127:88-94. (Corresponding author)
  77. Lin CW*, Tu PF, Hsiao NW, Chang CY, Wan L, Lin YT, Chang HW. Identification of a novel septin 4 protein binding to human herpesvirus 8 kaposin A protein using a phage display cDNA library. J Virol Methods. 2007,143:65-72. (Corresponding author)
  78. Lin CW*, Lin KH, Hsieh TH, Shiu SY, Li JY. Severe acute respiratory syndrome coronavirus 3C-like protease-induced apoptosis. FEMS Immunology & Medical Microbiology 2006, 46:375-380. (Corresponding author)
  79. Lin CW*, Lin KH, Lyu PC, Chen WJ. Japanese encephalitis virus NS2B-NS3 protease binding to phage-displayed human brain proteins with the domain of trypsin inhibitor and basic region leucine zipper. Virus Research 2006, 116:106-113. (Corresponding author)
  80. Lin CW*, Tsai FJ, Wan L, Lai CC, Lin KH, Hsieh TH, Shiu SY, Li JY. Binding Interaction of SARS Coronavirus 3CLpro Protease with Vacuolar-H+ ATPase G1 Subunit. FEBS Letter 2005, 579:6089-6094.(Corresponding author)
  81. Lin CW*, Tsai FJ, Tsai CH, Lai CC, Wan L, Ho TY, Hsieh CC, Lee Chao PD. Anti-SARS coronavirus 3C-like protease effects of Isatis indigotica root and plant-derived phenolic compounds. Antiviral Res. 2005, 68:36-42.(Corresponding author)
  82. Shih SR, Chen GW, Yang CC, Yang WZ, Liu DP, Lin JH, Chiu SC, Chen HY, Tsao KC, Huang CG, Huang YL, Mok CK, Chen CJ, Lin TY, Wang JR, Kao CL, Lin KH, Chen LK, Eng HL, Liu YC, Chen PY, Lin JS, Wang JH, Lin CW, Chan YJ, Lu JJ, Hsiung CA, Chen PJ, Su IJ.Laboratory-based surveillance and molecular epidemiology of influenza virus in Taiwan. J Clin Microbiol. 2005, 43:1651-61.
  83. Lin CW*, Tsai CH, Tsai FJ, Chen PJ, Lai CC, Wan L, Chiu HH, Lin KH. Characterization of trans- and cis-cleavage activity of the SARS coronavirus 3CLpro protease: basis for the in vitro screening of anti-SARS drugs. FEBS Letter 2004, 574(1-3):131-7. (Corresponding author)
  84. Lin CW*, Wu SC. Identification of Mimotopes of the Japanese Encephalitis Virus Envelope Protein Using Phage-Displayed Combinatorial Peptide Library. J. Mol. Micro. Biotech 2004, 8:34–42. (Corresponding author)
  85. Wu SC, Lin YJ, Chou JW, Lin CW. Construction and characterization of a Fab recombinant protein for Japanese encephalitis virus neutralization. Vaccine 2004, 23:163-171
  86. Wu SC,* Chiang JR, Lin CW. Novel Cell Adhesive Glycosaminoglycan-binding Proteins of Japanese Encephalitis Virus. Biomacromolecules 2004, 5:2160-2164
  87. Lin CW, Wu SC*. A functional epitope determinant on domain III of the Japanese encephalitis virus envelope protein interactions with neutralizing-antibody combining sites. Journal of Virology 2003, 77(4):2600-2606.
  88. Wu KP, Wu CW, Tsao YP, Kuo TW, Lou YC, Lin CW, Wu SC, Cheng JW. Structural basis of a flavivirus recognized by its neutralizing antibody: solution structure of the domain III of the Japanese encephalitis virus envelope protein. Journal Biolology Chemistry 2003, 278(46):46007-13.
  89. Wu SC*, Yu CH, Lin CW, Chu IM. The domain III fragment of Japanese encephalitis virus envelope protein: mouse immunogenicity and liposome adjuvanticity. Vaccine 2003, 21:2516-2522.
  90. Wu SC*, Lin CW, Lee SC, Lian WC. Phenotypic and genotypic characterization of the neurovirulence and neutroinvasiveness and a large-plaque attenuted Japanese encephalitis virus isolate. Microbes and Infection 2003, 5(6): 470-480.
  91. Wu SC*, Lin CW: Neutralizing Peptide Ligands Selected from Phage Displayed Libraries Mimic the Conformational Epitope on Domain III of the Japanese Encephalitis Virus Envelope Protein. Virus Research 2001, 76(1): 59-69.
  92. Lin CW*, Wu SC, Lee SC, Cheng KS. Genetic analysis and clinical evaluation of vacuolating cytotoxin gene A and cytotoxin-associated gene A in Taiwanese Helicobacter pylori isolates from peptic ulcer patients. Scandinavian Journal of Infectious Diseases 2000;. 32(1):51-7. (Corresponding author)
  93. Lin CW*, Chang YS, Wu SC, Cheng KS. Helicobacter pylori in gastric biopsies of Taiwanese patients with gastroduodenal diseases. Japanese Journal of Medical Science & Biology 1998; 51(1):13-23. (Corresponding author)
  94. Lin CW*, Yin PL, Cheng KS. Incidence and clinical manifestations of Campylobacter enteritis in central Taiwan. Chinese Medical Journal 1998; 61(6):339-45. (Corresponding author)
  95. Lin CW*, Wang SF, Cheng KS. Helicobacter pylori Isolates by Random Amplified Polymorphic DNA and Polymerase Chain Reaction-Restriction Fragment Length Polymorphism. Mid Taiwan Med J 1998; 3:101-7 (Corresponding author)
  96. Lin CW*, Wang HH, Chang YF, Cheng KS. Evaluation of CLO test and polymerase chain reaction for biopsy-dependent diagnosis of Helicobacter pylori infection. Chinese Journal of Microbiology & Immunology 1997; 30(4):219-27. (Corresponding author)
  97. Lin CW*, Chang YS, Lai PY, Cheng KS. Prevalence and heterogeneity of Helicobacter pylori in gastric biopsies of patients with gastroduodenal diseases. Chinese Journal of Microbiology & Immunology 1997; 30(1):61-71. (Corresponding author)
  98. Lin CW*, Lin TH, Sheen LY, Chung CH, Cheng KS: Diallyl sulfide as a potent inducer on the granulocytic/macrophagic differentiation of K562 human leukemic cells. Med J CMCH 1997 ;2:149-54 (Corresponding author)
  99. Lin CW*, Sun A, Jen J, Cheng KS: Biochemical differentiation and antimicrobial susceptibility of Stomatococcus mucilaginosus. J Biomed Lab Sci 1996;8:97-102. (Corresponding author)

II. Conference paper

  1. Cheng-Wen Lin. nhibition of TLR-7/8 signaling pathway by SARS coronavirus papain-like protease via K63-linked deubiquitination of TRAF3 and TRAF6. International Union of Microbiological Societies (IUMS) 2014-XVIth International Congress of Virology. 2014.7.27~08.02. Montréal, Canada. (Oral presentation, NSC 101-2320-B-039 -036 -MY3).
  2. Cheng-Wen Lin. Pro-fibrotic responses in A549 human lung epithelial cells and mouse lung tissues induced by SARS coronavirus papain like-protease. 32nd Annual Meeting of American Society for Virology. 2013.7.20~24. Penn State University, College Park, USA. (Oral presentation, NSC 101-2320-B-039 -036 -MY3).
  3. Cheng-Wen Lin. Anti-viral activity of a novel dihydro­furan carboxyl­ate compound against Japanese encephalitis virus. 2013 Positive Strand RNA Viruses Conference. 2013.04.28~05.03. Boston, USA. (Poster, NSC 99-2628-B-039-006-MY3)
  4. Cheng-Wen Lin. Identifying and characterizing novel biomarkers in oral cancer. Taiwan – Japan Joint Workshop on Biomedicine & Biomaterials for Short-Term Visit Program. 2013.1. National Chung Hsing University. (Oral presentation)
  5. Cheng-Wen Lin. Role of Coronavirus papain-like protease in SARS pathogenesis. GSU/CMU Biotech Symposium 2012. 2012.11-15~16.Georgia State University. (Invited Speaker, NSC 99-2628-B-039-006-MY3).
  6. Cheng-Wen Lin. Role of SARS Coronavirus papain-like protease in SARS pathogenesis. 2012 International Symposium on RNA Viruses: Virus-Host Interactions. 2012.11-09~10. Chang Gung University. (Invited Speaker, NSC 99-2628-B-039-006-MY3).
  7. Cheng-Wen Lin. Correlation between TGF beta-1 expression and proteomic profiling induced by SARS coronavirus papain like-protease.行政院國家科學委員會101年度「微免及檢驗醫學」學門學術交流研討會.2012.10.13. 台大醫院國際會議中心(Invited Speaker, NSC 99-2628-B-039-006-MY3).
  8. Cheng-Wen Lin. Proteomic analysis indicates the association of calreticulin down-regulation and cyclophilin A up-regulation with Type I interferon antagonism of Japanese encephalitis virus NS5 protein. 2nd World Congress on Virology. 2012.08-19~22. Las Vegas (USA). (Oral presentation, NSC 99-2628-B-039-006-MY3)
  9. Cheng-Wen Lin. Development of nanogold-based diagnostic test for Japanese encephalitis virus infection. Taiwan – Japan Joint Workshop on Biomedicine & Biomaterials for Short-Term Visit Program. 2012.1.7. China Medical University. (Oral presentation, NSC 99-2628-B-039-006-MY3)
  10. Cheng-Wen Lin. Antagonistic effects of SARS coronavirus PLpro in innate immune responses. 2011 年微生物學會年會病毒研討會-病毒與宿主交互作用及抗病毒機制新知研討會. 2011.12.17. 國立成功大學醫學院 (Oral presentation, NSC 99-2628-B-039-006-MY3)
  11. Cheng-Wen Lin. Heat shock protein 70 over-expression reduces interferon antagonist function of Japanese encephalitis virus NS5 protein. International Union of Microbiological Society 2011 congress (IUMS 2011): XV International Congress of Virology. 2011.9.11.~2011.9.16. (Poster, NSC 99-2628-B-039-006-MY3)
  12. Cheng-Wen Lin. Antagonism mechanism of interferon-induced response by SARS coronavirus papain-like protease. Ninth International Symposium on Positive-strand RNA Viruses.  2010.5.17~2010.5.21, Atlanta (Poster, NSC96-2320-B-039-008-MY3)
  13. Cheng-Wen Lin. Upregulation of cyclophilin A by the NS5 protein of Japanese Encephalitis Virus. 110th General meeting of American Society for Microbiology. 2010.5.23.~2010.5.27. (Poster, NSC96-2320-B-039-008-MY3)
  14. Lin Cheng-Wen, Li Shih-Wein. Inhibition of mitogen-activated protein kinase 3-type I interferon-STAT1 signaling by SARS coronavirus papain-like protease. IUMS2008: XIV. International Congress of Virology. 2008.8.10 ~ 2008.8.15. Istanbul, Turkey. (oral presentation) (NSC95-2320-B-039-008-MY3)
  15. Lin Cheng-Wen*, Shiu, Su-Lian. Molecular mechanism of apoptosis induced by Japanese encephalitis virus in human neuronal cells and monocytes. Keystone Symposia: Cell Biology of Virus Entry, Replication and Pathogenesis. 2008.4.13 ~ 2008.4.18. Victoria, Canada. (NSC95-2320-B-039-008-MY3)
  16. 陳俊偉、蕭乃文、林振文(Lin Cheng Wen)*. ISG15蛋白對於抑制日本腦炎病毒複製及其抗病毒分子機制研究.台灣微生物學會第40週年會員大會暨學術研討會2007.12.16.台大醫院國際會議中心
  17. 林振文(Lin Cheng Wen)*、蔡明宏(Ming-Hong Tsai)、黃素華(Su-Hua Huang) Evaluating the efficiency of PCR-based assays for diagnosis of Japanese encephalitis virus using gold nanoparticles中華民國醫事檢驗學會96年度年會大會暨學術研討會2007.11.11台大醫院國際會議中心
  18. Cheng-Wen Lin, Antiviral activity and interferon signaling induction of aloe-emodin against Japanese encephalitis virus and enterovirus 71. Sixth Meeting of Consortium for Globalization of Chinese Medicine (CGCM)August 29-30, 2007, Beijing, China
  19. Cheng-Wen Lin ,Molecular determinants of NS2B for activation of Japanese encephalitis virus NS3 protease 3rd Asian Dengue Meeting. 22-24 August 2007, Taipei, Taiwan
  20. Cheng-Wen Lin,Proteomic Analysis of Up-regulatory Proteins in Human Promonocyte Cells Expressing SARS Coronavirus 3C-Like Protease,7th Asia-Pacific Congress of Medical Virology,New Delhi, India,2006/11/13-2006/11/15 (oral presentation) (NSC94-2320-B-039-019)
  21. Cheng-Wen Lin,Comparison of Immunogenicity Elicited by Bacterial Recombinant Envelope Domain III and NS1 Proteins of Japanese Encephalitis Virus,2nd FEMS congress of European Microbiologists,Madrid,2006/7/4-2006/7/8 (poster)
  22. Cheng-Wen Lin,Prevalence of Human Herpesvirus 8 in Taiwan: a comparison among HIV-infected patients, diabetic patients and general population,Taiwan Society of Laboratory Medicine,Taipei,2006/11/18-2006/11/19 (oral presentation)
  23. Cheng-Wen Lin, SARS coronavirus 3CLpro protease binds vacuolar-H ATPase and incudes apoptosis,XIII International Congress of Virology,2005 IUMS,American Society for Microbiology,San Francisco, California, USA,2005/7/23-2005/7/28 (oral presentation) (NSC93-2320-B-039-051)
  24. Cheng-Wen Lin,Inhibition of SARS Coronavirus 3C-like Protease by Isatis Indigotica Root and Plant-derived Phenolic Compounds,International Society of Chemotherapy,Manila, Philippines,2005/6/3-2005/6/6 (poster)
  25. Cheng-Wen Lin,Japanese encephalitis virus NS2B-NS3 protease binding to human brain proteins with dibasic residue repeat motifs,Taiwan Society of Laboratory Medicine,Taipei,2005/11/4-2005/11/6 (oral presentation)
  26. Cheng-Wen Lin,Prevalence and phylogenetic analysis of human herpesvirus 8 in human ,Taiwan Society of Laboratory Medicine,Taipei,2005/11/4-2005/11/6 (poster)
  27. Cheng-Wen Lin,Functional Characterization of the SARS Coronavirus 3CLpro Protease,Chinese Society of Microbiology,台灣大學醫學院,2004/12/12 (poster)
  28. Lin CW, Wu SC. Functional and Structural Analysis of Neutralizing Epitopes on the Japanese Encephalitis Virus Envelope Protein. 6th Asia Pacific Congress of Medical Virology, Kuala Lumpur, Malaysia. Dec. 7-10, 2003 (oral presentation)
  29. Lin CW, Wu SC. Molecular and structural basis for mapping a neutralizing epitope of the Japanese encephalitis virus envelope protein using phage-displayed peptide libraries and molecular modeling analyses. Fifteenth symposium of the protein society, Philadelphia, Pennsylvania, USA. Julu-28-August 1, 2001. (poster)

III. Patents

  1. 吳夙欽 林振文 江政儒. 含醣胺素結合區之蛋白以及其形成方法(Glycosaminoglycan-binding protein and method to form it). 中華民國, I334419號

IV. Honors

  1. 林振文, 教育部103年服務學習獎勵計畫大專校院組績優行政人員(中華民國103年12月)
  2. 林振文, 科技部99-102年傑出學者養成計畫
  3. 李詩雯、林振文102年第二十一屆台灣微生物學會壁報論文獎第二名(中華民國102年12月)
  4. 林振文, 2012-2013中國醫藥大學研究傑出獎
  5. 林振文, 2011教育部顧問室大學跨學門科學人才培育銜接計畫.佳作 (中華民國100年12月)
  6. 林振文, 2011清華大學第一屆生命科學院傑出校友獎 (中華民國100年4月)
  7. 周于禎、林振文, 99年度台灣醫事檢驗學會優秀壁報論文獎 (中華民國99年10月)
  8. 林振文, 97、98年度中國醫藥大學教學卓越計畫績優獎
  9. 林振文,97年度台中市特殊優良教師獎(中華民國97年9月)

V. Books

  1. 劉建榮、林振文.臨床病毒學(Clinical Virology).合記圖書出版社. 中華民國100年3月

VI. Research grant

  1. 個別型,CMU102-ASIA-15,林振文(Lin Cheng Wen),花俊宏(Chun-Hung Hua),本校(含附醫),中草藥之組蛋白去乙醯化?抑制劑抗口腔癌的功效評估及其作用機轉,$500000,2014.8.1 ~ 2015.7.31
  2. 個別型,NSC101-2320-B-039-036-MY3,林振文(Lin Cheng Wen),國科會,SARS 冠狀病毒類木瓜蛋白?激活乙型轉型生長因子訊息及肺間質促纖維化潛力之研究,$1450000,2014.8.1 ~ 2015.7.31
  3. 個別型,NSC 102-2320-B-039-044-MY3,林振文(Lin Cheng Wen),賴建成,國科會,宿主細胞因子之離胺酸乙醯基化對日本腦炎病毒複製及病理機轉之影響,$1250000,2014.8.1 ~ 2015.7.31
  4. 個別型,MOST 103-2320-B-039-006-MY3,林應如(Ying-Ju Lin),蘇士哲、賴建成、陳錦華、李家琳(Chia-Lin Lee)、吳永昌(Yang-Chang Wu)、林振文(Lin Cheng Wen)、何宗融(Tsung-Jung Ho)、蔡輔仁(Fuu-Jen Tsai)、王任賢(Jen-Hsien Wang)、梁文敏(Wen-Miin Liang)、洪千惠,國科會,第一型愛滋病毒潛伏細胞活化之中藥活性分析與機轉探討,$1500000,2014.8.1 ~ 2015.7.31
  5. 學生參與計畫,MOST 103-2815-C-039-060-B,林振文(Lin Cheng Wen),國科會,以蛋白質體分析技術分析與登革熱病毒套膜蛋白結合之病毒受器及致病相關性細胞蛋白,$47000,2014.7.1 ~ 2015.2.28
  6. 校內其他單位控管計畫(例如:教卓計畫),NA,吳永昌(Yang-Chang Wu),郭盛助(Sheng-Chu Kuo)、林欣榮(Shinn-Zong Lin)、韓鴻志(Horng-Jyh Harn)、張建國(Jan-Gowth Chang)、林振文(Lin Cheng Wen)、湯智昕(Tang Chih-Hsin)、郭悅雄(Yueh-Hsiung Kuo)、陳悅生(Yueh-Sheng Chen)、林文川(Wen-Chuan Lin)、陳珠璜(Chu-Huang Chen)、林應如(Ying-Ju Lin)、侯庭鏞(Tin-Yun Ho)、顏宏融(Hung-Rong Yen),教育部,中醫藥研究中心(中草藥研究群組),$17100000,2014.4.1 ~ 2014.12.31
  7. 個別型,NSC101-2320-B-039-036-MY3,林振文(Lin Cheng Wen),國科會,SARS 冠狀病毒類木瓜蛋白?激活乙型轉型生長因子訊息及肺間質促纖維化潛力之研究,$1450000,2013.8.1 ~ 2014.7.31
  8. 非研究型計畫 (例如:課程計畫),NSC 102-2811-B-039-010,林振文(Lin Cheng Wen),國科會,SARS冠狀病毒類木瓜蛋白?激活乙型轉型生長因子訊息及肺間質促纖維化潛力之研究,$891118,2013.8.1 ~ 2014.7.31
  9. 個別型,NSC 102-2320-B-039-044-MY3,林振文(Lin Cheng Wen),國科會,宿主細胞因子之離胺酸乙醯基化對日本腦炎病毒複製及病理機轉之影響,$1250000,2013.8.1 ~ 2014.7.31
  10. 個別型,CMU101-ASIA-05,林振文(Lin Cheng Wen),本校(含附醫),腸病毒2A與3C 蛋白?抑制劑之快速篩藥系統,$680000,2013.6.1 ~ 2014.5.31
  11. 個別型,NSC 99-2314-B-039-008-MY3,張家寧(Sophia Chia-Ning Chang),林振文(Lin Cheng Wen)、楊美芳(Mei-Fang Yang),國科會,人類中胚層幹細胞的成骨作用,經Wnt訊息及奈米級羥基磷灰石而強化─非病毒性及病毒性載體的比較,$950000,2012.8.1 ~ 2013.7.31
  12. 學生參與計畫,CMU101-SR-66,林振文(Lin Cheng Wen),本校(含附醫),鑑定胜?抑制劑對SARS類木瓜蛋白?之細胞作用機制,$35000,2012.8.1 ~ 2013.2.28
  13. 個別型,CMU101-S-24,林振文(Lin Cheng Wen),本校(含附醫),新型人類冠狀病毒類木瓜蛋白?對Toll-like receptor訊息傳遞調控機制之研究(1/2),$220000,2012.8.1 ~ 2013.7.31
  14. 個別型,NSC 99-2628-B-039-006-MY3,林振文(Lin Cheng Wen),國科會,從日本腦炎病毒非結構蛋白NS5之功能與結構分析探索病毒致病之分子機轉及其在藥物開發應用,$1454000,2012.8.1 ~ 2013.7.31
  15. 個別型,NSC101-2320-B-039-036-MY3,林振文(Lin Cheng Wen),國科會,SARS 冠狀病毒類木瓜蛋白?激活乙型轉型生長因子訊息及肺間質促纖維化潛力之研究,$1400000,2012.8.1 ~ 2013.7.31
  16. ,CMU101-S-19,黃琮竣(Tsurng-Juhn Huang),林振文(Lin Cheng Wen)、周聖杰(Shen-Chieh Chou),本校(含附醫),台灣特有種細葉山艾天然物抗B型肝炎病毒之機制研究,$200000,2012.8.1 ~ 2013.7.31
  17. 學生參與計畫,NSC 101-2815-C-039-066-B,林振文(Lin Cheng Wen),國科會,鑑定胜?抑制劑對SARS類木瓜蛋白?之細胞作用機制,$47000,2012.7.1 ~ 2013.2.28
  18. 個別型,NSC 99-2628-B-039-006-MY3,林振文(Lin Cheng Wen),侯曼貞(Hour Mann-Jen),國科會,從日本腦炎病毒非結構蛋白NS5之功能與結構分析探索病毒致病之分子機轉及其在藥物開發應用,$1454000,2011.8.1 ~ 2012.7.31
  19. 個別型,NSC 99-2314-B-039-008-MY3,張家寧(Sophia Chia-Ning Chang),林振文(Lin Cheng Wen)、楊美芳(Mei-Fang Yang),國科會,人類中胚層幹細胞的成骨作用,經Wnt訊息及奈米級羥基磷灰石而強化─非病毒性及病毒性載體的比較,$950000,2011.8.1 ~ 2012.7.31
  20. 個別型,CMU100-S-33,林振文(Lin Cheng Wen),本校(含附醫),氟口奎諾酮類元化合物抗黃病毒之功效與分子機轉研究,$260000,2011.8.1 ~ 2012.7.31
  21. 非研究型計畫 (例如:課程計畫),100481AV,鍾景光(Jing-Gung Chung),林振文(Lin Cheng Wen),教育部,中區區域教學資源中心計畫(資源整合分享計畫)-04-主軸三(前膽生物技術實際驗室共享),$100000,2011.7.1 ~ 2012.12.31
  22. 非研究型計畫 (例如:課程計畫),NA,鍾景光(Jing-Gung Chung),林振文(Lin Cheng Wen),教育部,中區區域教學資源中心計畫(資源整合分享計畫)-04-主軸三(前膽生物技術實際驗室共享),$1000000,2011.7.1 ~ 2012.12.31
  23. 產學合作,0994267T,張家寧(Sophia Chia-Ning Chang),林振文(Lin Cheng Wen)、楊美芳(Mei-Fang Yang),加捷科技事業股份有限公司,人類臍帶中胚層幹細胞分離,$100000,2011.3.25 ~ 2012.3.24
  24. 學生參與計畫,99-A1,林振文(Lin Cheng Wen),教育部,99-A1 整合生物工程、演化生物、系統生物、轉譯醫學之BEST 學程,$800000,2011.1.1 ~ 2011.12.31
  25. 非研究型計畫 (例如:課程計畫),NA,鍾景光(Jing-Gung Chung),林振文(Lin Cheng Wen),教育部,99年度中區區域教學資源中心計畫-建構特殊實驗室共享平台,$81000,2010.10.1 ~ 2011.7.31
  26. 學生參與計畫,CMU99-大專-32,林振文(Lin Cheng Wen),本校(含附醫),腸病毒71型2A蛋白?抑制干擾素訊息傳遞之研究,$35000,2010.8.1 ~ 2011.2.28
  27. 學生參與計畫,CMU99-大專-29,林振文(Lin Cheng Wen),本校(含附醫),腸病毒71型3C蛋白?活性分析及其抑制劑篩選,$35000,2010.8.1 ~ 2011.2.28
  28. 個別型,CMU99-NSC-08,林振文(Lin Cheng Wen),本校(含附醫),製備及分析具備標靶癌細胞多功能性的奈米鈣油體,$200000,2010.8.1 ~ 2011.7.31
  29. 個別型,NSC 99-2628-B-039-006-MY3,林振文(Lin Cheng Wen),國科會,從日本腦炎病毒非結構蛋白NS5之功能與結構分析探索病毒致病之分子機轉及其在藥物開發應用,$1454000,2010.8.1 ~ 2013.7.31
  30. 個別型,NSC 99-2314-B-039-008-MY3,張家寧(Sophia Chia-Ning Chang),林振文(Lin Cheng Wen)、楊美芳(Mei-Fang Yang),國科會,人類中胚層幹細胞的成骨作用,經Wnt訊息及奈米級羥基磷灰石而強化─非病毒性及病毒性載體的比較,$950000,2010.8.1 ~ 2011.7.31
  31. 個別型,CMU99-S-23,林振文(Lin Cheng Wen),本校(含附醫),功能蛋白質體學策略探討日本腦炎病毒非結構蛋白NS5在病毒致病機轉的角色,$300000,2010.8.1 ~ 2011.7.31
  32. 個別型,CMU98-P-03-M,林振文(Lin Cheng Wen),本校(含附醫),蛋白質體學分析磷酸化和泛素化蛋白變化探討SRAS冠狀病毒類木瓜蛋白?對抗病毒反應的影響,$175000,2010.5.1 ~ 2011.4.30
  33. 個別型,CMU98-P-03,林振文(Lin Cheng Wen),本校(含附醫),蛋白質體學分析磷酸化和泛素化蛋白變化探討SRAS冠狀病毒類木瓜蛋白?對抗病毒反應的影響,$175000,2010.5.1 ~ 2011.4.30
  34. 整合型項下子計畫(主持人),NA,鍾景光(Jing-Gung Chung),林振文(Lin Cheng Wen),,99年度中區區域教學資源中心計畫-建構特殊實驗室共享平台(003主軸三),$810000,2010.2.1 ~ 2011.6.30
  35. 學生參與計畫,99-A1,林振文(Lin Cheng Wen),教育部,整合生物工程、演化生物、系統生物、轉譯醫學之BEST學程,$720000,2010.1.1 ~ 2010.12.31
  37. 產學合作,098426O3,張家寧(Sophia Chia-Ning Chang),林振文(Lin Cheng Wen)、楊美芳(Mei-Fang Yang),育成中心加捷科技事業股份有限公司,肝功能修補動物實驗,$1000000,2009.12.1 ~ 2010.11.30
  38. 個別型,NSC 96-2320-B-039-008-MY3,林振文(Lin Cheng Wen),國科會,以系統生物分析技術探索SARS冠狀病毒蛋白脢PLPRO及3CLPRO對UBIQUITIN訊息傳遞機制之影像,$1304000,2009.8.1 ~ 2010.7.31
  39. 個別型,NSC 98-2324-B-039-006,林振文(Lin Cheng Wen),國科會,大黃與板藍根及其成份抗流行性感冒之分子機制研究,$750000,2009.8.1 ~ 2010.7.31
  40. 個別型,CMU98-S-05,林振文(Lin Cheng Wen),本校(含附醫),TOLL-LIKE受體訊息免疫反應在日本腦炎病毒感染之研究,$350000,2009.8.1 ~ 2010.7.31
  41. 學生參與計畫,CMU98-大專-39,林振文(Lin Cheng Wen),本校(含附醫),從噬菌體呈現胜?庫鑑定抗SARS冠狀病毒,$30000,2009.8.1 ~ 2010.2.28
  42. 學生參與計畫,NSC 98-2815-C-039-039-B,林振文(Lin Cheng Wen),國科會,從噬菌體呈現胜?庫鑑定抗SARS冠狀病毒,$47000,2009.7.1 ~ 2010.2.28
  43. 整合型(召集人、總主持人),CMU97-343,林振文(Lin Cheng Wen),本校(含附醫),總計畫:標靶導向開發中醫藥製劑(含子計畫7:蛋白體質技術分析功能性中草藥抗腫瘤及抗微生物機制:以大黃抗乳癌及抗流行性感冒病毒研究為例),$600000,2009.5.1 ~ 2010.4.30
  44. 個別型,NSC 96-2320-B-039-008-MY3,林振文(Lin Cheng Wen),國科會,以系統生物分析技術探索SARS冠狀病毒蛋白脢PLPRO及3CLPRO對UBIQUITIN訊息傳遞機制之影像,$1281000,2008.8.1 ~ 2009.7.31
  45. 個別型,CMU97-140,林振文(Lin Cheng Wen),本校(含附醫),以蛋白質體分析技術探索日本腦炎病毒誘發細胞發炎及細胞凋亡之泛素訊息傳遞機制(2),$400000,2008.8.1 ~ 2009.7.31
  46. 整合型項下子計畫(主持人),CMU97-114,林振文(Lin Cheng Wen),本校(含附醫),以系統生物全方位技術分析唾液、血清及組織生物標幟以開發口腔癌之診斷、治療急癒後評估指標--子計畫一:利用蛋白質體及奈米技術開發人口腔癌之唾液腫瘤標記診斷試劑(2/3),$460000,2008.8.1 ~ 2009.7.31
  47. 整合型(召集人、總主持人),CMU97-113,林振文(Lin Cheng Wen),本校(含附醫),以系統生物全方位技術分析唾液、血清及組織生物標幟以開發口腔癌之診斷、治療急癒後評估指標(2/3),$450000,2008.8.1 ~ 2009.7.31
  48. 整合型項下子計畫(主持人),CMU97-CMC-020,林振文(Lin Cheng Wen),本校(含附醫),結合干擾素免疫調節分析及病毒蛋白?抑制分析之抗病毒平台快速篩選中醫藥抗病毒感染之有效成份,$450000,2008.8.1 ~ 2009.7.31
  49. 校內其他單位控管計畫(例如:教卓計畫),P3-4-CMU,林振文(Lin Cheng Wen),教育部,研究學習群之推廣,$392000,2008.8.1 ~ 2009.7.31
  50. 校內其他單位控管計畫(例如:教卓計畫),302_96P,鍾景光(Jing-Gung Chung),林振文(Lin Cheng Wen),,前膽生物技術實驗室共享平台--主軸三:建構特殊實驗室共享平台,$4285000,2008.8.1 ~ 2009.12.31
  51. 個別型,NSC 96-2320-B-039-008-MY3,林振文(Lin Cheng Wen),國科會,以系統生物分析技術探索SARS冠狀病毒蛋白脢PLPRO及3CLPRO對UBIQUITIN訊息傳遞機制之影像,$1226000,2007.8.1 ~ 2009.7.31
  52. 個別型,CMU96-067,林振文(Lin Cheng Wen),本校(含附醫),以蛋白質分析技術探索日本腦炎病毒誘發細胞發炎及細胞凋亡之泛素訊息傳遞機制,$350000,2007.8.1 ~ 2008.7.31
  53. 整合型(召集人、總主持人),CMU95-316,林振文(Lin Cheng Wen),本校(含附醫),以系統生物全方位技術分析唾液、血清及組織生物標幟以開發口腔癌之診斷、治療急癒後評估指標,$450000,2007.6.1 ~ 2008.5.31
  54. 整合型(召集人、總主持人),CMU95-317,林振文(Lin Cheng Wen),本校(含附醫),以系統生物全方位技術分析唾液、血清及組織生物標幟以開發口腔癌之診斷、治療急癒後評估指標--子計畫一:利用蛋白質體及奈米技術開發人口腔癌之唾液腫瘤標記診斷試劑,$460000,2007.6.1 ~ 2008.5.31
  55. 校內其他單位控管計畫(例如:教卓計畫),09648001,鍾景光(Jing-Gung Chung),林振文(Lin Cheng Wen),教育部,學科資源構面:特殊實驗室共用平台,$302978,2007.4.1 ~ 2008.10.31
  56. 校內其他單位控管計畫(例如:教卓計畫),09649002,鍾景光(Jing-Gung Chung),林振文(Lin Cheng Wen),,學科資源構面:特殊實驗室共用平台,$2378162,2007.4.1 ~ 2008.10.31
  57. 整合型(召集人、總主持人),CMU95-237,林振文(Lin Cheng Wen),本校(含附醫),標靶癌症治療之多功能奈米粒子的開發,子計畫一:奈米煤介之HER-2標靶癌症治療細胞模式,$990000,2006.12.1 ~ 2007.7.31
  58. 個別型,NSC95-2320-B-039-019,林振文(Cheng-Wen Lin),國科會,SARS冠狀病毒蛋白脢3CLpro與PLpro之分子致病機制探討:細胞週期,細胞凋亡及發炎訊號,$902000,2006.8.1 ~ 2007.7.31
  59. 個別型,CMU95-054,林振文(Lin Cheng Wen),本校(含附醫),干擾素免疫調節中草藥成份抗A型流感病毒感染之研究,$400000,2006.8.1 ~ 2007.7.31
  60. 個別型,CMU95-070,林振文(Lin Cheng Wen),本校(含附醫),日本腦炎病毒誘發細胞發炎及細胞凋亡之研究,$300000,2006.8.1 ~ 2007.7.31
  61. 整合型(召集人、總主持人),CMU95-153,林振文(Lin Cheng Wen),本校(含附醫),以系統生物學思維之蛋白質體分析技術探索SARS冠狀病毒與宿主細胞間交互作用,$500000,2006.8.1 ~ 2007.7.31
  62. 整合型(召集人、總主持人),CMU95-152,林振文(Lin Cheng Wen),鄭如茜(Ju Chien Cheng)、楊翠青(Tsuey-Ching Yang),本校(含附醫),建立蛋白質體學研究平台探討重要致病性微生物基因體之致病機制、診斷標的與新開發,$500000,2006.8.1 ~ 2007.7.31
  63. 整合型(召集人、總主持人),NSC95-2745-B-039-003-URD,林振文(Cheng-Wen Lin),國科會,提昇私校研發能量專案計畫-癌症的基礎與臨床研究-子計畫九:人類 疹病毒第八型引發惡性腫瘤之增生機制研究(3/3),$600000,2006.8.1 ~ 2007.7.31
  64. 個別型,CMU95-220,陳昭賢,林振文(Lin Cheng Wen),本校(含附醫),PSEUDONOCARDIA AUTOTROPHICA BCRC12444中CYTOCHROME P450 MONOOXYGENASE生物轉換能力及生理角色的探討,$200000,2006.8.1 ~ 2007.7.31
  65. 個別型,NSC95-2320-B-039-045-,萬磊(Lei Wan),賴建成(Chien-Chen Lai)、林振文(Lin Cheng Wen),國科會,從訊號傳遞和蛋白質交互作用來研究甲型干擾素(IFN-ALPHA)和乙型干擾素(IFN-BETA)在肝細胞中作用機轉的異同,$1020000,2006.8.1 ~ 2007.7.31
  66. 校內其他單位控管計畫(例如:教卓計畫),P3-4,林振文(Lin Cheng Wen),教育部,研究學習群之推廣,$1265000,2006.8.1 ~ 2007.7.31
  67. 整合型(召集人、總主持人),95-2815-C-039-015-B,林振文(Cheng-Wen Lin),(林育存),國科會,利用噬菌體呈現技術研究日本腦炎病毒套膜蛋白與人腦基因庫的交互作用,$32000,2006.7.1 ~ 2007.1.31
  68. 個別型,DMR-96-107,白禮源(Li-Yuan Bai),邱昌芳(Chang-Fang Chiu)、林振文(Lin Cheng Wen),本校(含附醫),Sonic hedgehog 訊息路徑與血液惡性腫瘤的關係,$250000,2006.7.1 ~ 2007.6.30
  69. 個別型,NSC 94-2320-B-039 -010 -,林振文(Cheng-Wen Lin),國科會,日本腦炎病毒蛋白體誘發神經細胞發炎及凋亡之研究,$550000,2005.8.1 ~ 2006.7.31
  70. 個別型,CMU94-086,林振文(Cheng-Wen Lin),本校(含附醫),日本腦炎病毒誘發細胞發炎及細胞凋亡之研究 (1/2),$250000,2005.8.1 ~ 2006.7.31
  71. 整合型(召集人、總主持人),NSC 94-2745-B-039 -003 -URD,林振文(Cheng-Wen Lin),鍾景光(Chung, Jing-Gung),國科會,提昇私校研發能量專案計畫-癌症的基礎與臨床研究-子計畫九:人類,$600000,2005.8.1 ~ 2006.7.31
  72. 個別型,NSC94-2320-B-039-042,萬磊(Lei Wan),林振文(Lin Cheng Wen)、賴建成(Chien-Chen Lai)、蔡輔仁(Fuu-Jen Tsai)、蔡進發,國科會,甲型干擾素(IFN-ALPHA)和乙型干擾素(IFN-BETA)在肝細胞中抗病毒作用機轉研究,$1023000,2005.8.1 ~ 2006.7.31
  73. 個別型,94-2815-C-039-011-B,林振文(Cheng-Wen Lin),(徐欣怡),國科會,利用突變技術分析日本腦炎病毒之NS2B-NS3蛋白酵素活性,$42000,2005.7.1 ~ 2006.2.28
  74. 個別型,CMU-93-MT-04,林振文(Cheng-Wen Lin),本校(含附醫),利用蛋白質體策略研究日本腦炎病毒之中樞神經致病機轉 (2/2),$100000,2004.8.1 ~ 2005.7.31
  75. 個別型,NSC93-2320-B-039-051,林振文(Cheng-Wen Lin),國科會,抗病毒中草藥之開發:篩選干擾素促進劑,$830000,2004.8.1 ~ 2005.7.31
  76. 整合型(召集人、總主持人),93-2745-B-039-004-URD,林振文(Cheng-Wen Lin),國科會,提昇私校研發能量專案計畫-癌症的基礎與臨床研究-子計畫九:人類 疹病毒第八型引發惡性腫瘤之增生機制研究(1/3),$600000,2004.8.1 ~ 2005.7.31
  77. 個別型,DOH93-DC-1036,王任賢(Wang,Jen-Hsien),林振文(Cheng-Wen Lin),08,腸病毒,流感病毒及SARS合約實驗室,$3850000,2004.1.1 ~ 2004.12.31
  78. 個別型,CMU92-MT-03,林振文(Cheng-Wen Lin),本校(含附醫),利用蛋白質體策略研究日本腦炎病毒之中樞神經致病機轉,$100000,2003.8.1 ~ 2004.7.31
  79. 個別型,NSC92-2314-B-039-030,林振文(Cheng-Wen Lin),國科會,利用噬菌體表達人腦cDNA基因庫研究日本腦炎病毒蛋白與宿主細胞因子之功能性交互作用,$521700,2003.8.1 ~ 2004.7.31
  80. 個別型,NSC92-2751-B-039-009-Y,蔡長海,林振文(Cheng-Wen Lin)、蔡輔仁(Tsai,Fuu-Jen)、陳建仲(Chen,Jian-Jung)、賴建成(Lai,Chien-Chen),國科會,建立轉錄調節序列表現及蛋白質體系統於治療嚴重急性呼吸道症候群之中草藥有效成分篩選,$1612400,2003.8.1 ~ 2004.7.31
  81. 個別型,CMC91—MT-05,林振文(Cheng-Wen Lin),本校(含附醫),鑑定日本腦炎病毒套膜蛋白之肝素結合區域,$180000,2002.8.1 ~ 2003.7.31
  82. 個別型,CMC90-MT-05,林振文(Cheng-Wen Lin),本校(含附醫),抗日本腦炎病毒套膜蛋白之單株抗體E3.3的中和機制研究,$160000,2001.8.1 ~ 2002.7.31
  83. 個別型,CMC89-MT-02,林振文(Cheng-Wen Lin),本校(含附醫),利用定點突變及分子模擬分析日本腦炎套膜蛋白第三抗原決定區域之不連續中和性抗原決定位的分子構,$180000,2000.8.1 ~ 2001.7.31
  84. 個別型,CMC88-MT-01,林振文(Cheng-Wen Lin),本校(含附醫),基因工程改造日本腦炎病毒套膜蛋白質之類似抗原決定位為病毒診斷試劑及疫苗,$120000,1999.8.1 ~ 2000.7.31
  85. 個別型,CMC87-MT-02,林振文(Cheng-Wen Lin),本校(含附醫),利用噬菌體表達peptide來鑑定日本腦炎病毒之抗原力的抗原決定位,$157000,1998.8.1 ~ 1999.7.31
  86. 個別型,CMC86-MT-02,林振文(Cheng-Wen Lin),本校(含附醫),幽門旋曲桿菌之抗藥性及異質性,$100000,1997.8.4 ~ 1998.7.31
  87. 個別型,85-066,林振文,本校(含附醫),以PCR鑑定胃組織中的幽門旋曲桿菌及其胃潰瘍的致病因子,$50000,1996.8.1 ~ 1997.7.31



  1. Post-Doctoral fellowship
  2. Ph D students
  3. Master students
    碩二:陳奕潔、平家鳳、莊  婕、張郡恩
  4. Undergraduate students
  5. Alumni
    Visiting Post-Doctoral fellowship: 張擁軍 (2010)
    Research assistants:邱華浩 (2003-2004)、林冠勳 (2004-2005)、莊佩馨 (2007-2008) 、鄒博成(2008-2009)、邱婷怡(2009-2010)、邱曼慈(2009-2010)、平家鳳(2010-2010)
    PhD:白禮源(2007~2011), 李詩雯(2007~2012)
    Master:林冠勳 (2003-2004)、張鈞萍(2004-2006)、鄭傑文(2004-2006)、塗炳峰(2004-2006)、李詩雯(2005-2007)、許素連(2005-2007)、吳佳芳(2005-2007)、蔡明宏(2005-2007)、李姿穎(2006-2008)、宋明璋(2006-2008)、陳俊偉(2006-2008)、鄭美秀(2006-2008)、鄒依芸(2006-2008)、陳宏綸(2008-2009)、顧心元(2008-2009)、邱曼慈(2008-2009)、周于楨(2008-2009)、蕭莉馨(2009-2010)、謝京伶(2009-2010)、林妍冠(2009-2010)、周偉生(2009-2010)、呂鎧任(2009~2011) 、謝宗翰(2009-2012)、黃千甄(2010-2012)、張祐鈞(2010~2012)、廖俊銘(2010-2012)
    Undergraduate students:蔡忠憲(2003-2005)、徐欣怡(2003-2006)、李政怡(2003-2006)、劉光庭(2004-2006)、蔡靜誼(2005-2006)、黃宏達(2004-2007)、林育存(2004-2007)、王佳文(2004-2007)、林韋華(2005-2008)、洪培紋(2006-2008) 、蘇玉如(2007-2009)、林應雅(2007-2009)、陳瑜萱(2008-2010)、平家鳳(2008-2010)、趙思涵(2008-2010)、許瑄珉(2009-2011)、陳信樺(2008-2011)、莊  婕(2008-2011)、歐陽瑋婷(2009-2011)、范力升(2009-2011)、楊季哲(2009-2011)、李宜霖 (2009-2012)、許孟庭 (2009-2012)、 陳佩慈 (2009-2012)、莊鈞茹(2010-2012)



對一般人來說,要去熟悉一個新的環境是需要一些時間的,而像我這種神經超大條的脫線女王更是不用說,一開始的那幾個月簡直就像是一場大災難,而這一切全都辛苦了必須要想盡辦法善後的冠勳學長,雖然第一天我們被他磅礡的氣勢嚇到,不過可能是被天真無邪又糊里糊塗的學妹們所感化吧,過不多久學長便露出本性,變得既搞笑又悶騷。不過我這個剛入門的新手還是一天到晚闖禍,最高紀錄還曾經一口氣打破兩套western的鑄膠玻璃,另外還曾經因為把cell culture的medium濃度配錯,最後只好把原來的一罐泡成三罐,還破紀錄的讓當時心情很鬱悶的學長衝到走廊上破口大罵:「你是在泡什麼東西!!!」那陣子我的心情可以說是非常的低落,明明已經非常努力想要做好一件事情,卻老是搞砸,連想幫個忙都會造成別人的困擾,再加上跟了實驗後時間一下子無法調適,導致我二上很悽慘的被當了兩科,雪上加霜的情況下,一度想放棄跟實驗,幸好老師適時的對我伸出援手,體貼地叫學長不要給我太多的壓力,讓我能度過那一段黑暗期,並且一路走到最後。
當然啦,實驗室並不只有那些沮喪的回憶,我仍然獲得了許多,最重要的莫過於western blot,雖然一開始憑著新手的好手氣幫學長跑了幾張還不錯的電泳,但是鑄膠對我來說一直是一道無法跨越的障礙,於是我只要一看到有人要跑電泳,就會自告奮勇要幫忙鑄膠,但由於是現做現跑,所以通常都因為時間有限而作罷。直到有一天傍晚,慷慨的光庭學長願意給我機會幫他鑄膠,才讓事情有了轉變,那天我努力的看著配方調配,配錯了再重來,膠不凝再重來,膠漏掉了再重來,牙齒拔壞了再重來,就這樣一遍又一遍重來,終於在光庭學長慎重考慮要自己接手的那一刻完成了,簡單的兩片膠就讓我做到晚上七點多,但是這樣的付出卻讓我超越了那道無形的障礙,並且在兩年後的研究所口試有了回報。從此以後光庭學長也變成我實驗上的好伙伴,我們常常互相討論如何才能封出一片完美無瑕的膠,當時還研究出一堆奇奇怪怪的方法呢!而老師也會在我跑完一片電泳後不吝嗇地給予鼓勵及肯定,對我來說,這是一種力量,一種給了我自信的力量,一種讓我知道我並不是只會闖禍的力量,一種讓我知道我有所進步並有所成長的力量。


在實驗室期間主要以日本腦炎病毐套膜蛋白為研究目標,並以”利用噬菌體呈現技術研究日本腦炎病毒套膜蛋白與人類基因庫的交互作用”通過國家科學委員會95年度大專生專題研究計畫的審核,獲得補助經費、執行國科會大專生專題研究計畫,對Phage display、ELISA、PCR、Cloning、Protein purification、Cell culture、Co-immunoprecipitation、Co-transfection等技術都駕輕就熟,唯有實際操作,才能同時了解實驗原理並增加實驗熟練度。初步實驗結果將在95年度中華民國醫事檢驗年會以”Apoptotic Stress Induced by the Envelope Protein of Japanese Encephalitis Virus”為題作論文發表。此外還參與”Functional Interaction of Human Herpesvirus 8 Kaposin Protein with Septin-4 Identified from Phage Display cDNA Libraries”的研究,習得許多實驗技巧,收穫良多。

實驗室心情留言 (III):黃宏達(2004-2007)

回憶起三年前,一個懵懵懂懂的大一生,從北港上來台中找進入實驗室的老師,對於老師所做的研究不了解,心中充滿了問號和不安,但是我心中只有一個想法,就是我要找尋我自己喜歡做的研究 — 病毒,因為在2002經歷了SARS的風暴,我發現病毒竟然是如此的可怕,如果可以預先了解和防範它,就可以避免那麼多人的喪生,所以我便選擇了林振文老師的實驗室,也開始了我的研究生活。
到了大三,那可是我大學最精彩的一頁,或許,經過一年的相處,早已跟學長姐打成一片,對於實驗室的喜怒哀樂,我們都一起承擔和享受,對於實驗的不順利,我們一起煩心、一起發洩情緒,而出遊的快樂,我們一起享受、一起高歌起舞。在實驗方面,由於老師對融合瘤並沒有完全放棄,所以我又開始展開融合瘤的實驗,不過這次由我獨立作業,可是這次實驗仍然沒有成功,以汙染的結果作收,坦白說,這次實驗接近要成功了,其實還蠻可惜的,緊接著,國科會有大專生參與研究的計劃申請,林老師很鼓勵我們去撰寫計劃和申請,雖然這次沒有被錄取,但我也學習到如何撰寫計劃的知識,而大三下的時間馬上到了,從原本免疫方面改學習到分子生物方面的實驗技術,並且老師也開始給我們有自己主題的實驗,從最簡單的PCR到Western blot,全部都是自己完成不假他人之手,也奠定了我往後實驗的基礎。

訪學交流留言 (I):福建省疾病預防控制中心 張擁軍 (2010.11-2010.12)

1.  開啟深層次學術交流的新模式。不同於其他短時間參觀或考察,我這次的訪學進修的特點是一個人到林教授實驗室進行2個月的實驗研究。由於之前沒有類似的案例可循,學術交流中心張大為組長和賴又瑄小姐克服各種困難,高效率聯繫和準備申請文書,在短時間內完成了審批。我的成功申請案例,有助於今後大陸和臺灣互相派遣學者,實實在在地開展實驗研究,而不是走馬看花似的考察。
2.   實地瞭解臺灣學者在蟲媒病毒基礎研究。臺灣和福建省的地理和生態相似之處甚多,每年仍然有日本腦炎、登革熱案例。臺灣學者歷來比較重視蟲媒病毒的基礎研究,在國際病毒學界享有較高聲譽。通過這兩個月的實地學習,感受到這些成績的取得,一方面來自實驗室負責人的嚴格要求、實驗室之間的團結協作,同時也與歷屆研究生的辛勤工作和學校的大環境都密切相關。
3.   探索雙方研究合作領域及模式。通過2個月的學習和交流,我們認識到大陸和臺灣蟲媒病毒實驗室各自的一些長處和不足,由此看到了今後雙方在醫學病毒學基礎研究領域存在的合作空間。雙方的合作方向,除了互通資訊,更要揚長避短,實現優勢互補。根據這段時間的商議,我們和林教授初步達成了近期在日本腦炎診斷試劑研發,以及今後長期在日本腦炎病毒複製機理研究等領域的合作意向。今後雙方將採用及時通報實驗進展、互享實驗材料以及共同發表論文,並嘗試共同申請科研經費,互相派遣學者進行短期研究等合作模式。
4.   感受臺灣及中國醫藥大學的人才培養制度及青年學生的刻苦學習。這兩個月在中國醫藥大學校園內,體驗到年輕大學生們豐富多彩的校園生活,更感受到大學嚴格的人才培養制度和青年學生刻苦學習的氛圍。尤其是部分大學三年級、四年級學生進入實驗室從事初級研究課題,不僅使理論知識得到及時的應用,更培養了學生的研究興趣,因此不少學生能夠進入研究所深造。同時,不同於大陸大部分研究生免學費,臺灣青年學生儘管要支付學費和不菲的生活費,仍然努力學習,踴躍報考研究所。在校學生普遍比較勤奮,每天都有不少學生工作到深夜才離開實驗室,令人欽佩。



除了個人求學的意志,求學歷程一直能遇到良師,也讓他選擇走向學術這條路,其中啓蒙恩師為陽明大學吳榮燦教授。由大二到研究所,在吳榮燦教授實驗室一待就是六年,實驗進行及同儕間的研究分享,讓他愛上研究。之後,嚮往清華自由及人文學風,吸引他來就讀生科院博士班, 成為吳夙欽老師之指導學生。每週一次個別進研究室與老師談實驗進度及準備畢業時,每天進研究室坐在老師旁,跟著老師一同修改論文,就是在清華最好的回憶。林振文教授對於老師的用心及無私教誨,讓他學會對尖端科學必須要有追求與堅持,嚴謹的科學邏輯還要加上靈活及巧思的研究,最後還必須俱備學術倫理及智財觀念。這些從吳老師身上學習到的研究典範,影響了他一輩子。林振文教授提到當他的畢業論文被 Journal of Virology 接受的那一下午,與吳老師兩人一同到新竹廟口吃豆花,享受那種登峰後簡單的快樂,就算是在緊湊的博士班生活中難得的靜謐與享受。 





  1. Biotechnology
    There has been rapid progress in recombinant DNA technology over the last few years, particularly in the area of large-scale biology (genomics and related disciplines). The increasing integration between gene manipulation and genomics is embraced in this course. This important course consists of basic and advanced gene-manipulation techniques, genome analysis, genomics, transcriptomics, proteomics, and metabolomics, as well as the applications of these fascinating technologies.
  2. Molecular Virology
    The course presents major areas of modern virus research, and how the knowledge thus gained can be applied to the practical task of controlling viral diseases.
  3. Molecular diagnosis
    This course will learn modern molecular technologies for diagnosing human diseases, in particular infectious diseases, inherited diseases and oncology.
    Educational objectives are to contrast the mechanisms of viral pathogenicity with those of bacterial pathogenicity, to develop the concept of the target organ in viral pathogenicity, to stress the role of immune mechanisms in virus-induced cell damage, and to define the role of viruses in teratology.